Exacerbation of Bleomycin-Induced Injury and Fibrosis by Pneumonectomy in the Residual Lung of Mice

Journal of Surgical Research

Volumn 154, Issue 2, 2009, Pages 336-344

  Kakizaki, Toru ^a   Kohno, Mitsutomo ^b   Watanabe, Masazumi ^b   Tajima, Atsushi ^b   Izumi, Yotaro ^b   Miyasho, Taku ^c   Tasaka, Sadatomo ^b   Fukunaga, Koichi ^b   Maruyama, Ikuro ^d   Ishizaka, Akitoshi ^b   Kobayashi, Koichi ^b  

^a Kanagawa National Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c RAKUNO GAKUEN UNIVERSITY   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

acute lung injury acute respiratory distress syndrome (ALI ARDS); bleomycin; high mobility group box 1; induction therapy; lung cancer; lung resection

Indexed keywords

BLEOMYCIN; COLLAGEN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY PERMEABILITY; CONTROLLED STUDY; HISTOPATHOLOGY; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG FLUID; LUNG INJURY; LUNG LAVAGE; LUNG RESECTION; LUNG WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; THORACOTOMY;

ACUTE LUNG INJURY; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CHEMOKINE CCL2; CHEMOKINE CCL5; CHEMOKINE CXCL1; COLLAGEN; EXTRAVASCULAR LUNG WATER; HMGB1 PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PULMONARY FIBROSIS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349207414     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.06.021     Document Type: Article

References (45)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Watanabe S., Asamura H., Suzuki K., et al. Recent results of postoperative mortality for surgical resections in lung cancer. Ann Thorac Surg 78 (2004) 999 discussion 1002
3. Wright G., Manser R.L., Byrnes G., et al. Surgery for non-small cell lung cancer: Systematic review and meta-analysis of randomised controlled trials. Thorax 61 (2006) 597
4. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153
5. Roth J.A., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673
6. Mansour Z., Kochetkova E.A., Ducrocq X., et al. Induction chemotherapy does not increase the operative risk of pneumonectomy!. Eur J Cardiothorac Surg 31 (2007) 181
7. Roberts J.R., Eustis C., Devore R., et al. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 72 (2001) 885
8. Depierre A., Milleron B., Moro-Sibilot D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 (2002) 247
9. Martin J., Ginsberg R.J., Abolhoda A., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. Ann Thorac Surg 72 (2001) 1149
10. Perrot E., Guibert B., Mulsant P., et al. Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection. Ann Thorac Surg 80 (2005) 423
11. Leo F., Solli P., Veronesi G., et al. Does chemotherapy increase the risk of respiratory complications after pneumonectomy?. J Thorac Cardiovasc Surg 132 (2006) 519
12. Venuta F., Anile M., Diso D., et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 31 (2007) 714
13. Leo F., Solli P., Spaggiari L., et al. Respiratory function changes after chemotherapy: An additional risk for postoperative respiratory complications?. Ann Thorac Surg 77 (2004) 260 discussion 265
14. Takeda S., Funakoshi Y., Kadota Y., et al. Fall in diffusing capacity associated with induction therapy for lung cancer: A predictor of postoperative complication?. Ann Thorac Surg 82 (2006) 232
15. Gopal R., Starkschall G., Tucker S.L., et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 56 (2003) 114
16. Miller K.L., Zhou S.M., Barrier Jr. R.C., et al. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 56 (2003) 611
17. Horning S.J., Adhikari A., Rizk N., et al. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study. J Clin Oncol 12 (1994) 297
18. Castro M., Veeder M.H., Mailliard J.A., et al. A prospective study of pulmonary function in patients receiving mitomycin. Chest 109 (1996) 939
19. Maas K.W., van der Lee I., Bolt K., et al. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41 (2003) 345
20. Bhalla K.S., Wilczynski S.W., Abushamaa A.M., et al. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 161 (2000) 17
21. Blum R.H., Carter S.K., and Agre K. A clinical review of bleomycin-a new antineoplastic agent. Cancer 31 (1973) 903
22. Rabinowits M., Souhami L., Gil R.A., et al. Increased pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations. Am J Clin Oncol 13 (1990) 132
23. Smith R.E., Strieter R.M., Phan S.H., et al. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J Leukoc Biol 64 (1998) 528
24. Smith R.E., Strieter R.M., Phan S.H., et al. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J Immunol 153 (1994) 4704
25. Suwabe A., Takahashi K., Yasui S., et al. Bleomycin-stimulated hamster alveolar macrophages release interleukin-1. Am J Pathol 132 (1988) 512
26. Tokuda A., Itakura M., Onai N., et al. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol 164 (2000) 2745
27. Yara S., Kawakami K., Kudeken N., et al. FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol 124 (2001) 77
28. Zhang K., Gharaee-Kermani M., Jones M.L., et al. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol 153 (1994) 4733
29. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248
30. Park J.S., Gamboni-Robertson F., He Q., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290 (2006) C917
31. Yamada S., and Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 375 (2007) 36
32. Kim J.Y., Park J.S., Strassheim D., et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 288 (2005) L958
33. Ueno H., Matsuda T., Hashimoto S., et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170 (2004) 1310
34. Suda K., Kitagawa Y., Ozawa S., et al. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: A predictor of clinical course after surgery?. Dis Esophagus 19 (2006) 5
35. Ashcroft T., Simpson J.M., and Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41 (1988) 467
36. Yamada S., Inoue K., Yakabe K., et al. High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 49 (2003) 1535
37. Endo M., Oyadomari S., Terasaki Y., et al. Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol 285 (2003) L313
38. Saito F., Tasaka S., Inoue K.I., et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 38 (2008) 566
39. Karmiol S., and Phan S.H. Fibroblast and cytokines. In: Kunkel S.L., and Remick D.G. (Eds). Cytokines in Health and Disease (1992), Dekker, New York, NY 271-296
40. Oppenheim J.J., Zachariae C.O., Mukaida N., et al. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 9 (1991) 617
41. Ogawa E.N., Ishizaka A., Tasaka S., et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med 174 (2006) 400
42. Abraham E., Arcaroli J., Carmody A., et al. HMG-1 as a mediator of acute lung inflammation. J Immunol 165 (2000) 2950
43. Harada K., Hamaguchi N., Shimada Y., et al. Use of sulfur hexafluoride, SF6, in the management of the postpneumonectomy pleural space. Respiration 46 (1984) 201
44. Andersson U., Wang H., Palmblad K., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192 (2000) 565
45. Fiuza C., Bustin M., Talwar S., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101 (2003) 2652